Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PrimeC · PrimeC 748

Small molecule · developed by NeuroSense Therapeutics

Phase 2 Most advanced trial (none active)
NRSN Developer
2 Registered trials

What is PrimeC?

PrimeC is an extended release fixed dose combination of ciprofloxacin and celecoxib. It is studied in pharmacokinetics and Alzheimer disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PrimeC 748
Drug type
Small molecule
Therapy area
Neurology
Developer
NeuroSense Therapeutics Ltd. (NRSN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06185543 Phase 2 Alzheimer Disease Terminated NRSN
NCT05436678 Phase 1 Pharmacokinetics Completed NRSN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alzheimer DiseasePharmacokinetics

More from NeuroSense Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NRSN page.

Follow NRSN, the company behind PrimeC

See NRSN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NRSN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.